Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hawthorne

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Blood Advances|May 8, 2020
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignanciesStephen M Ansell, Ian Flinn, Matthew H Taylor, et al.
Emergency Radiology|February 13, 2023
Evaluation of computed tomography perfusion and angiogram use in stroke evaluation for thrombectomy at a community emergency department settingCal D Zahn, Hayden L Smith, Jonathan R Hurdelbrink, et al.
Medical Care|April 1, 1981
Planning health services for a city jail: impact of contractual services on men's sick callR W Freeman, R E Gollub, M Wolski, et al.
Allergy|February 20, 2022
Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer studyDiego Alvarado, Marcus Maurer, Richard Gedrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid TumorsHoward A Burris, Jeffrey R Infante, Stephen M Ansell, et al.
Cancer|January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanomaPatrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.
Journal for Immunotherapy of Cancer|August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumorsRachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Blood Advances|May 8, 2020
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignanciesStephen M Ansell, Ian Flinn, Matthew H Taylor, et al.
Emergency Radiology|February 13, 2023
Evaluation of computed tomography perfusion and angiogram use in stroke evaluation for thrombectomy at a community emergency department settingCal D Zahn, Hayden L Smith, Jonathan R Hurdelbrink, et al.
Medical Care|April 1, 1981
Planning health services for a city jail: impact of contractual services on men's sick callR W Freeman, R E Gollub, M Wolski, et al.
Allergy|February 20, 2022
Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer studyDiego Alvarado, Marcus Maurer, Richard Gedrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid TumorsHoward A Burris, Jeffrey R Infante, Stephen M Ansell, et al.
Cancer|January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanomaPatrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.
Journal for Immunotherapy of Cancer|August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumorsRachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Pageof 6